β¨ Medicinal Consents
NEW ZEALAND GAZETTE
No. 11
274
Product:
Gutron
Active Ingredient(s):
Midodrine hydrochloride 5mg
Dosage Form:
Tablet
NZ Sponsor:
Douglas Pharmaceuticals Limited
Manufacturer(s):
Nycomed Austria GmbH, Linz, Austria
Note: This consent is valid for 2 years from 30 April 2000.
Dated this 2nd day of February 2000.
G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
g022
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:
Schedule
Product:
Angiomax
Active Ingredient(s):
Bivalirudin 100mg
Dosage Form:
Powder for injection
NZ Sponsor:
The Medicines Company
Manufacturer(s):
Ben Venue Laboratories Inc, Bedford, Ohio, United States of America
Note: This consent is valid for 2 years from the date of publication of this notice.
Product:
Calciferol Strong
Active Ingredient(s):
Ergocalciferol 1.25mg equivalent to 50,000units
Dosage Form:
Tablet
NZ Sponsor:
PSM Healthcare Limited
Manufacturer(s):
PSM Healthcare Limited, Wiri, Auckland
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 2nd day of February 2000.
G. R. BOYD,
Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
g023
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the schedule hereto:
Schedule
Product:
Lemsip Chesty Cough Medicine
Active Ingredient(s):
Guaiphenesin 10mg/mL
Dosage Form:
Linctus
NZ Sponsor:
Reckitt & Colman (New Zealand) Limited
Manufacturer(s):
Reckitt & Colman Products Limited, Hull, North Humberside, United Kingdom
Product:
NovoRapid NovoLet
Active Ingredient(s):
Insulin aspart 100U/mL
Dosage Form:
Solution for injection
NZ Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturer(s):
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Product:
NovoRapid Penfill
Active Ingredient(s):
Insulin aspart 100U/mL
Dosage Form:
Solution for injection
NZ Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturer(s):
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Product:
NovoRapid
Active Ingredient(s):
Insulin aspart 100U/mL
Dosage Form:
Solution for injection
NZ Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturer(s):
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2000, No 11
Gazette.govt.nz —
NZ Gazette 2000, No 11
β¨ LLM interpretation of page content
π₯
Renewal of Provisional Consent to the Distribution of a New Medicine
(continued from previous page)
π₯ Health & Social Welfare2 February 2000
Medicines Act 1981, Gutron, Midodrine hydrochloride, Douglas Pharmaceuticals, Nycomed Austria
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare2 February 2000
Medicines Act 1981, Angiomax, Bivalirudin, The Medicines Company, Ben Venue Laboratories
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare2 February 2000
Medicines Act 1981, Lemsip Chesty Cough Medicine, Guaiphenesin, Reckitt & Colman
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare2 February 2000
Medicines Act 1981, NovoRapid NovoLet, Insulin aspart, Novo Nordisk
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare2 February 2000
Medicines Act 1981, NovoRapid Penfill, Insulin aspart, Novo Nordisk
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare2 February 2000
Medicines Act 1981, NovoRapid, Insulin aspart, Novo Nordisk
- G. R. Boyd, Chief Advisor, Safety and Regulation